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Abstract: The importance of next generation sequencing (NGS) rises in cancer research as accessing this key technology becomes
easier for researchers. The sequence data created by NGS technologies must be processed by various bioinformatics algorithms within
a pipeline in order to convert raw data to meaningful information. Mapping and variant calling are the two main steps of these analysis
pipelines, and many algorithms are available for these steps. Therefore, detailed benchmarking of these algorithms in different scenarios
is crucial for the efficient utilization of sequencing technologies. In this study, we compared the performance of twelve pipelines
(three mapping and four variant discovery algorithms) with recommended settings to capture single nucleotide variants. We observed
significant discrepancy in variant calls among tested pipelines for different heterogeneity levels in real and simulated samples with
overall high specificity and low sensitivity. Additional to the individual evaluation of pipelines, we also constructed and tested the
performance of pipeline combinations. In these analyses, we observed that certain pipelines complement each other much better than
others and display superior performance than individual pipelines. This suggests that adhering to a single pipeline is not optimal for
cancer sequencing analysis and sample heterogeneity should be considered in algorithm optimization.
Key words: Clinical bioinformatics, next generation sequencing, cancer, mapping algorithms, variant discovery algorithms

1. Introduction
Cancer is a major threat to human health that leads to
millions of deaths each year worldwide (Siegel et al.,
2019). This malady is well-documented in human history
since ancient Egyptian civilization and remains a major
adversary of humanity (Mukherjee, 2010). Cancer is a
result of the transformation of cells through which they
obtain uncontrolled growth. Understanding the molecular
changes that lead to this transformation is critical to
prevent and treat cancer. Changes in chromosomal
abnormalities were observed in cancer since the early
studies of Boveri at the beginning of the 20th century
(Baltzer, 1964). Recent improvements in sequencing
technologies made the fast and inexpensive mapping of
cancer genomes possible (Tucker et al., 2009). This was a
major step in cancer research and led to large-scale cancer
genome profiling studies such as The Cancer Genome
Atlas (TCGA) (Weinstein et al., 2013) and International
Cancer Genome Consortium (ICGC) (Zhang et al.,
2011). These studies confirmed the existence of mutations

that arise in parallel to tumor formation and identified
recurrent mutations that potentially drive increased cell
proliferation and motility.
Massively parallel (next-generation) sequencing
technologies are based on shredding DNA into small
fragments and determining the nucleotide sequence in
these fragments. These short reads are mapped to the
reference genome to identify the genome sequence of the
sample. In cancer samples, genome sequences from tumor
and nontumor tissue belonging to the same individual
are compared to find cancer-specific somatic mutations.
These two steps (mapping and variant calling) constitute
the two major steps of cancer sequencing analyses, and
many algorithms were developed for these tasks. These
algorithms are combined in software pipelines, which
take raw sequencing data as input and produce cancerspecific changes as output. Different mapping and variant
discovery algorithms have different assumptions and
priorities. As a result, the number and type of variants
identified by these algorithms might vary significantly.
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This makes detailed testing of constructed pipelines for
different situations an essential task for efficient utilization
of sequencing technologies.
Benchmarking sequencing pipelines is an active
field of research. Extensive studies on the performances
of aligners and variant callers have been carried out
(Hatem et al., 2013; O’Rawe et al., 2013; Pirooznia et al.,
2014; Hwang et al., 2015; Hwang et al., 2019). Hwang
et al. (2019) comprehensively evaluated a combination
of 7 mapping and 10 variant calling algorithms using
high confidence variants as validation datasets from
three different platforms. The authors suggested that the
choice of variant calling algorithm is crucial. Hwang et
al. (2015) analyzed discordant variant calling results on
different datasets. They proposed to use different pipelines
for different datasets. Due to the availability of precise
evaluation metrics, these studies concentrate on germline
mutation callings.
In addition to these works, several studies evaluate
somatic mutation calling with tumor-normal samples
(Wang et al., 2013; Hofmann et al., 2017; Ellrott et al.,
2018; Chen et al., 2020). However, unlike germline calling
tests, somatic variant callers lack a strict ground truth
data set. Thus, different studies have followed different
methodologies to overcome this problem. Some studies
used simulated samples to measure the efficiency, some
others used Sanger sequencing for validation (Roberts et
al., 2013; Cai et al., 2016; Krøigård et al., 2016; Bohnert et
al., 2017). A review on variant callers by Xu (2018) showed
the potential biases and dependencies of these methods
and datasets. The study suggested that a collection of real
cancer genomes with high confidence variant datasets
could greatly benefit benchmarking studies. Moreover,
most of the benchmarking studies in cancer sequencing
focus on variant callers but not aligners.
In an open-source cloud project, Ellrott et al. (2018)
compared 10 variant callers on 10,510 tumor/normal pairs
from 33 cancer types in the TCGA collection of wholeexome sequencing data. In total, the data set contained
around 4 million variants after filtering nonexonic and
possible germline variants. The authors used a different
pipeline procedure to select validated variants like applying
allele fractions and read count thresholds from different
data types (WGS, WXS, Targeted, and RNA). Alioto et al.
(2015) conducted a benchmarking study on lymphocytic
leukemia and medulloblastoma tumor/normal samples
for whole-genome sequencing data. They recommend
optimizing aligner/variant caller combination and
combining multiple variant callers. Hofmann et al. (2017)
examined different variant callers and aligners for wholegenome sequencing datasets. Their validation method was
generated by nine variant calling algorithms in simulated

kidney tumor datasets. This study tested VC algorithms
in different coverage levels and compared variant allele
frequencies. Besides, the authors reveal that a combination
of different pipelines outperforms a single pipeline.
Here, our study takes into account the effect of aligners
and variant callers in cancer sequencing samples at different
heterogeneity levels. We also analyzed the effect of pipelines
combinations, where we combined three mapping (Bwa
(Li and Durbin, 2009); Bowtie2 (Langmead and Salzberg,
2012); and Novoalign1) and four variant calling algorithms
(Mutect2 (v4.1.0) (Cibulskis et al., 2013); Varscan (v2.3.9)
(Koboldt et al., 2012); SomaticSniper (Larson et al., 2011);
Strelka2 (v2.9.10) (Saunders et al., 2012)). This resulted
in twelve mapping-variant calling combinations labeled
as “Bwa_Mutect2, Bwa_Varscan” etc. Although these
algorithms were introduced a long time ago and more
recent algorithms exist, these algorithms get updated
regularly and are still considered as the most frequently
used, state of art models. A recent paper, that reviews the
best practices for variant calling in clinical sequencing, lists
most practiced and cited variant callers which includes all
the variant callers in this article (Koboldt, 2020). Several
other latest articles, which compares the performances of
variant calling pipelines in various scenarios, have chosen
to benchmark VarsScan2, Mutect2 and Strelka2 (Wang
et al., 2019; Chen Z et al., 2020). Therefore, we chose to
evaluate the most commonly practiced workflows.
Recently, we have published a dataset of fifty-five highresolution homogeneous and heterogeneous glioblastoma
samples. (Baysan et al., 2017). These samples share a
substantial portion of mutations which allows us to
declare these mutations as validated mutations; since for
an algorithm identifying a non-existing mutation twice
in two independent samples is very unlikely. This dataset
had four different sample types: (i) primary tumor samples
from different parts of a glioblastoma tissue block, (ii) in
vitro polyclone samples cultured from tumor stem cell
lines of the primary tumor, (iii) in vivo polyclone samples
obtained from mouse xenografts after in vitro polyclones
were injected to a mouse brain and formed a tumor, (iv) in
vitro monoclone samples obtained from in vitro polyclone
samples through isolation of single cells and subsequent
culturing until there are enough cells for exome
sequencing. The availability of these samples presented us
with a unique opportunity to test sequencing pipelines at
different heterogeneity levels. For the mentioned pipelines,
first, we compared the mutation lists through pairwise
comparisons. Mutations were declared “validated” when
they were detected in two independent samples. Validated
mutations were used to evaluate the performance of each
pipeline and different pipeline combinations.
http://www.novacraft.com/products/novoalign/[accessed 23 08
2020]
1
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Multiple studies have also been conducted on somatic
indel variant callers, as well (Hasan et al., 2015; Kim et
al., 2017; Chen et al., 2020). However, due to a couple
of reasons, accurate indel classification is far more
challenging than SNVs. First of all, aligners tend to map
reads to multiple mismatches rather than indel sequences
because of the short read lengths (Ghoneim et al., 2014).
Secondly, false positive rates are higher compared to SNVs
as a result of both read distribution and identical repetitive
sequences (Narzisi et al., 2014). A study done by Fang et al.
(2014), shows that indel and structural variant detection
in exome-sequencing is relatively unreliable. In another
article, inter-caller agreement of 5 variant callers on indel
variants is as low as 0.01% which proves the inconsistency
(Krøigård et al., 2016). Due to these reasons, only SNVs
were included in this study.
We have also simulated realistic samples with known
mutations and compared these results with our original
samples. In order to observe the effect of mutation
frequencies on variant detection, we have generated
tumors with low, medium, and high tumor purity.
2. Materials and methods
2.1. Samples
Sequenced samples were generated with Illumina pairedend sequencing technology at Ambry Genetics. Each
paired-end read comprised of 8 million reads, 100bp read
length and mean quality scores were between 34 and 38.
Supplementary Figure 1 shows an example of standard
read quality and read length. The dataset was consisted of
a total of 50 glioblastoma samples; primary tumors from
seven regions of a single tumor, 13 in vivo polyclones,
seven in-vitro polyclones, 19 in vitro monoclones, and
four secondary monoclones. A matched blood sample was
sequenced as a matched normal sample. All sequenced
reads were mapped to the human reference genome
version GRCh38. The coverage of samples was between
50×–100× (Baysan et al., 2017). Randomly selected four
samples’ coverage distribution with different mapping
tools were shown in Supplementary Figure 2.
2.2. Pipelines
A typical cancer sequencing pipeline includes following
steps; quality control and trimming, mapping,
preprocessing and variant calling. In this study, we created a
set of pipelines for which FASTQ formatted raw sequenced
data was used as input. The output of each pipeline was
a variant containing VCF file (Figure 1(A)). The pipeline
software was implemented in Python language and can be
downloaded from our GitHub page2. Each pipeline uses
different algorithms for mapping and variant calling steps.

https://github.com/MBaysanLab/GenomicsPipeline [accessed 23
08 2020]
2
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All other steps and tools in the pipelines were identical,
namely quality control of reads via FastQC3, trimming
by FASTP (Chen et al., 2018) and SAMTools (Li et al.,
2009), and preprocessing according to recommended best
practices using GATK4 (Van der Auwera et al., 2013).
Pipelines include three alternative mapping algorithms
namely BWA, Bowtie2, and Novoalign and four alternative
variant calling algorithms i.e. Mutect2, Varscan,
SomaticSniper, and Strelka2. Each pipeline was designed
to contain a combination of one mapping and one variant
calling algorithm. Therefore, twelve pipelines were created
to represent all combinations (Supplementary Table 1).
All algorithms were used with their default parameters to
evaluate their performance with their default setup. For
the sake of fairness, minimum variant read depth was fixed
to 10 for each pipeline.
2.3. Simulating tumor samples
To compare our results in the real dataset to an
experimental simulation, we generated simulated reads
using NEAT read simulator (Stephens et al., 2016). This
tool generates FASTQ and VCF files with tumor/normal
samples, thus enabling us to extend the scope of our
benchmarking study. We utilized the same exome regions
in the real dataset and pooled all the variants detected by
any of our pipelines in the real samples. NEAT generates
reads with random mutations by using this variant pool
and exome regions. We created around 4800 variants in
three different purity environment.
First, we constructed a normal (nontumor) FASTQ
file with 80× coverage, then created two different tumor
files with 20× and 80× coverages. The 20× and 80× tumor
files contains 4864 and 4764 mutations, respectively.
By combining 20× tumor file with 80× normal reads,
firstly tumor file is created with %20 tumor purity. Then
80× tumor sample was merged with 80× normal sample
and produced a tumor with 50% purity. Lastly, only the
80× tumor sample was used without merging with the
normal sample to have a sample with 100% tumor purity.
By extracting the variants presented in the tumor VCFs,
we constructed the list of the synthetic somatic variants.
All three purity environments share the similar number
of mutations that are produces by the same mutation
model inferred from the original variant pool. Thus, in
this simulation we investigated how different pipelines
perform finding mutations in different tumor purities.
3. Results
Each of the twelve pipelines was applied on 50 tumor
samples, which resulted in 600 runs in total. We evaluated
the pipelines according to the number of variants found.

https://www.bioinformatics.babraham.ac.uk/projects/fastqc
[accessed 23 08 2020]
3
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Pipelines that used Novoalign as the mapping algorithm
found more variants than BWA and Bowtie2 pipelines.
Among all, Bowtie2 pipelines had the least number of
discovered variants (Figure 1(B)). When we group samples
by variant calling algorithms, SomaticSniper found the
least number of variants while Strelka2, and Varscan
found more variants (Figure 1(C)). Primary samples
(except Parental-5) have fewer mutations compared to
other samples, which is expected due to the high level
of heterogeneity and potential nontumor contamination
in these samples. We also observed a similar pattern in
our four monoclone samples (Figure 2). Since the overall
number of variants was smaller in these samples, the
number of validated variants were also less.
Next, we analyzed the similarities of identified variants
between different pipelines on different sample types.
In Figure 3, cosine similarity matrices for each pipeline
for each sample type are displayed (see Supplementary
Figure 3 and Supplementary Figure 4 for Pearson and
Jaccard correlations). In primary tumor and polyclone

samples (both in vitro and in vivo), pipelines that
included SomaticSniper and Varscan as variant discovery
algorithms clustered together regardless of the applied
mapping algorithm. Pipelines that included Strelka2 and
Mutect2 produced most of the time similar results when
used with the same mapping algorithm. On the other hand,
in monoclone samples, pipelines that used Novoalign
clustered together and were clearly separated from the
rest. For the pipelines that used BWA and Bowtie2 as
alignment algorithms, variant discovery algorithms were
the dominant factor with respect to clustering.
After the comparison of the obtained variants for
different pipelines, we utilized the multiple detections
of variants in different samples as a validation method.
Based on these validated variants, precision, recall, and
F1 scores were computed for each pipeline (Figure 4). A
true positive (TP) variant is defined as the detection of a
validated variant, a false positive (FP) variant is defined as
the detection of a nonvalidated variant, and a false negative
(FN) is defined as the lack of detection of a validated

Figure 1. (A) The workflow of a simple Cancer DNA-Seq analysis pipeline including the steps and input/output files. (B) Boxplot of
average mutation counts by the mapping algorithms. Y-axis represents the average variant number. Since 4 variant callers were used, the
mean of these four variant callers with the same mapping algorithm represents the average value for each sample. The X-axis shows the
corresponding mapping algorithm. (C) Boxplot of average mutation counts by the variant callers. Y-axis represents the average variant
number. Since 3 mapping algorithms are used, the mean of these three mapping algorithms with the same variant caller represents the
average value for each sample. The X-axis shows the corresponding variant callers.
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Figure 2. Heat map of the number of detected variants for each sample by the pipelines. Rows represent the samples and
columns represent pipelines. The color scale displays the total number of variants found by the pipeline in a sample (dark color
indicates more variants found and light color indicates fewer variants found).

variant by the pipeline. There are genuinely unique variants
specific to a sample, which creates an underestimate in our
scores. Since the problem applies to all pipelines, its effect
can be discarded.
We observed that pipelines that include Novoalign
have high recall and less precision (Figures 4 and 5). In
other words, both false positive and true positive counts

118

are higher in these pipelines, which is concordant with
the overall high number of detected variants in Novoalign
pipelines. Quantitatively, pipelines that use Novoalign have
recall scores around 0.35 while pipelines with Bowtie2
were around 0.15 and pipelines with BWA were around
0.25. This suggests that Novoalign pipelines capture
significantly more variants out of all the validated variants.

KISAKOL et al. / Turk J Biol

Figure 3. Clustered similarity matrices for each sample type. Cosine similarity values are represented in the cells along with
the color scale (dark colors ‒ higher cosine similarity and light colors ‒ lower cosine similarity among pairs). Dendrograms
indicate hierarchical clusters among pipelines. Thus, pipelines with a higher similarity clustered together.

On the other hand, while BWA and Bowtie2 pipelines had
a precision of ~0.90, meaning that 90% of their findings
were validated variants while Novoalign performed worse
with a precision of 0.65.
After evaluating the general patterns of algorithms,
we focused on the individual pipeline performances with
respect to recall and precision. Among the single pipelines,
Novoalign-Strelka2 had the best recall score on most of the
samples (44/46), while Bowtie2-SomaticSniper had the
best precision score (20/46). Due to the low recall numbers

for other algorithms, Novoalign-Strelka2 performed best
in terms of F1 scores in 32 samples with ~0.39 on average
(Table).
3.1. Combination of pipelines
Each algorithm relies on different assumptions and has
different priorities, resulting in different strengths and
weaknesses in terms of variant detection. This makes the
combination of different pipelines a potential solution for
blending the strengths of different pipelines (Alioto et al.,
2015; Hofmann et al., 2017). Since we obtained low recall
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Figure 4. Precision (A) and recall (B) box plots for individual samples in each sample type.

scores and high precision scores, we hypothesized that
we can improve the recall rates of individual pipelines by
constructing the union of pipelines. Our aim was to find
a point where recall and precision scores are balanced to
achieve an optimal F1 score.
We calculated the performance of every possible
combination of different pipeline unions separately for each
sample. Combinations that achieve the best F1 score for
each sample were recorded. The most successful pipeline
combinations are displayed on Table for (i) individual
pipelines (ii) two pipeline combinations, and (iii) three
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pipeline combinations. Best pipeline combinations for
every situation can be seen in Supplementary Table 2 and
3. As the number of pipelines in a combination increases
up to six, F1 scores tend to get higher by a good margin
(Figure 6). However, after six combinations, marginal loss
on precision scores cannot be covered with recall gain.
F1 scores are either insubstantially increased or slightly
decreased as the combination number extends beyond six.
Our results show that F1 scores can be boosted up
to around 0.7 with proper pipeline combinations. We
found that Bowtie2_Varscan with Novoalign_Strelka2

KISAKOL et al. / Turk J Biol

Figure 5. Scatter plots for precision-recall scores. Y-axis represents precision and X-axis shows recall. Colors indicate mapping
algorithm choice while markers denote variant callers. (A) represents all the samples (46) with different pipelines (12) while (B)
represents four subplots according to sample types.

/ Novoalign_SomaticSniper can complement very well
in monoclone and polyclone samples. Especially on
polyclone samples, this combination outperforms every

other combination in almost all samples. Although this
combination produces the best results for most of the
cases, primary tumor samples have a different pattern.
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Table. Top five pipelines according to F1 scores for three cases. After calculating every possible combination, a pipeline combination
with the best F1 score is kept for each sample. Table includes the top five pipeline combination selections that have the most occurrences
for 46 samples.
Pipeline #1

Pipeline #2

Pipeline #3

Parental

in vitro –
in vitro – in vivo –
Total
MonoClone PolyClone PolyClone

Novoalign_Strelka2

-

-

6

13

6

7

32

Bowtie2_Varscan

-

-

0

2

1

3

6

Novoalign_SomaticSniper -

-

0

2

0

2

4

Novoalign_Varscan

-

-

0

1

0

1

2

Bwa_Mutect2

-

-

1

0

0

0

1

Bwa_SomaticSniper

-

-

0

1

0

0

1

Bowtie2_Varscan

Novoalign_SomaticSniper -

0

5

3

6

14

Bowtie2_Varscan

Novoalign_Strelka2

-

0

4

3

3

10

Bwa_Mutect2

Novoalign_Strelka2

-

4

0

0

0

4

Novoalign_Varscan

Novoalign_Strelka2

-

0

1

1

2

4

Bowtie2_SomaticSniper

Novoalign_Strelka2

-

0

3

0

0

3

Bowtie2_Varscan

Novoalign_Strelka2

Novoalign_SomaticSniper 0

5

1

2

8

Bowtie2_Varscan

Bwa_Strelka2

Novoalign_SomaticSniper 0

1

2

3

6

Bowtie2_Varscan

Bwa_SomaticSniper

Novoalign_Strelka2

0

2

1

2

5

Bwa_Mutect2

Bwa_SomaticSniper

Novoalign_Strelka2

4

0

0

0

4

Bowtie2_SomaticSniper

Novoalign_Mutect2

Novoalign_Strelka2

0

4

0

0

4

BWA_Mutect2 and Novoalign_Strelka2 combination
performs better on primary samples. Overall, Bowtie2 and
Novoalign pipelines complement very well on monoclones
and polyclones while BWA and Novoalign pipeline unions
are better choices on primary tumor samples.
3.2. Results on simulated variants
We simulated around 4800 mutations in three different
purity environments to compare our results with the
synthetic data where the real variants were known (materials
and methods). In environments with low and high purity,
we observed that variant caller choice has a strong effect
on the number of variants found (Supplementary Figure
5). SomaticSniper finds far less mutations in low purity
environment, while Mutect2 discovers fewer variants
in high purity. Precision ratios were high in all pipelines
with 99.99% accuracy in low-medium purity and 95+% in
the high purity. On the other hand, recall ratios declined
significantly as the purity of the environment decreased.
Supplementary Figure 6 clearly demonstrates the huge
variance in recall scores between the pipelines. Novoalign_
SomaticSniper achieves 100% precision but with only 10%
recall and Bwa_Strelka2 performs 99% precision with 75%
recall scores. Strelka2 outperformed other variant callers on
low purity environment with over 70% recall performance
in all three aligner choices, where Varscan, Mutect2, and
SomaticSniper only achieved 48%, 27%, and 10% on the
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average respectively. When variants of different pipelines
were combined in the low purity environment, F1 scores
increased considerably similar to the original samples
(Supplementary Figure 7). These suggest that using a single
pipeline results in highly variable outcomes depending on
the variant caller chosen and combining multiple pipelines
achieve better performance. Finally, we compared the
similarity of the variants that were discovered in different
pipelines. In this case, pipelines were clustered based on
the variant caller similar to parental tumors and polyclonal
samples (Supplementary Figures 8-10).
4. Discussion
Precision medicine relies on detailed profiling of patient
samples. Recent developments in sequencing technologies
allowed the measurement of DNA and RNA with an
unprecedented resolution at dropping prices. This makes
sequencing an ideal tool for studying genetic diseases
such as cancer. Raw data obtained by massively parallel
sequencing devices is large, error-prone, and highly
redundant. It can be converted to useful information only
with proper bioinformatics analysis, which makes best
practices for analyzing sequencing data crucial for the
effective utilization of sequencing technologies.
In this study, we evaluated the performance of the
most popular cancer sequencing pipelines. We used high-

KISAKOL et al. / Turk J Biol

Figure 6. Distribution of the F1 scores depending on the number of pipelines used in combination. Colors indicate sample
types and Y-axis represents the best F1 score while X-axis represents the combination selection. The first plot shows every
combination ranging from using only one pipeline to using the union of all the 12 possible pipelines. The second plot is the
clipped version until the combination of six.

resolution heterogeneous and homogeneous samples that
belong to a single tumor to measure the performances of
sequencing algorithms for different heterogeneity levels in
a realistic scenario (as an alternative, we could have used
single-cell sequencing, but resolution drops significantly
due to amplification). Cancer sequencing analysis consists
of two major steps, namely mapping and variant discovery.
In our work, we used the most popular algorithms that we
could obtain for both steps. After selecting three mapping

and four variant discovery algorithms, we constructed
and evaluated twelve pipelines as the combinations of
these algorithms to assess the coherence between different
mapping and variant discovery algorithms.
Sequencing algorithms can usually be executed with
different parameters to give users the opportunity to
adapt the algorithms to different scenarios. We used the
default or recommended parameters for each algorithm
to assess their general performance. This created a slight
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problem for our comparisons since certain pipelines had
found more variants than others. Especially pipelines that
include Novoalign had more variants, while pipelines
that used Bowtie2 had fewer variants. We could change
some parameters to make the count of identified variants
more similar, but we preferred to keep the recommended
parameters to keep our comparison more practical since
most of the users will prefer default settings.
An important and distressing result was the limited
overlap between the variants that different pipelines
discover. Even with most homogeneous samples that
were cultured from a single cell, we observed a limited
overlap (as low as 50%), which matches up with the results
of similar study reporting an inter-caller agreement rate
around 50% on exome samples (Krøigård et al., 2016).
We tried to use commonly identified variants in different
samples as a metric of correctness since a false discovery
of the identical variant in different samples is unlikely. We
defined these commonly detected variants as “validated
variants” and computed recall and precision rates for each
pipeline based on these variants. We observed a clear
precision and recall trade-off among pipelines. Pipelines
that report more variants demonstrated higher recall but
lower precision rates. To quantify the marginal gain of
reporting extra variants we calculated the F1 scores for each
pipeline based on recall and precision rates, which comes
out to be lower than 0.5 for most of the pipelines. Previous
studies have shown that combining outputs of several
variant callers increases performance on detecting variants
and amplifies the F1 score (Rashid et al., 2013; Kim et al.,
2014). Similar results also appeared in our study in which
higher F1 scores could be obtained by combining (union)
identified variants of different pipelines. We did extensive
experiments to determine the pipeline combinations
that produced the highest F1 score. Our results indicate
that combinations that include five or six pipelines with
complementary algorithms (such as Bowtie2-Varscan and
Novoalign-Strelka2) perform best for identifying variants.

Many different benchmarking studies have been
conducted to assess the accuracy of somatic variant callers
or aligners. Nevertheless, the heterogeneity of cancer
samples can affect the results considerably. Therefore, in
this study, we aimed to perform a benchmarking study
of both different variant callers and aligners in different
heterogeneity levels on real and simulated datasets. After
illustrating the benchmark results, we proposed using a
combination of different tools to utilize the somatic variant
calling pipelines’ performances.
For the evaluation of mutations, we declare the
mutations that were discovered by only a single pipeline as
false positives. We are aware that some real variants might
be captured only by a single pipeline and thus may not be
real false positives. However, this was a very unlikely event
considering very high precision rates and low number
of false positive mutations, which was concordant with
detailed sampling of a single tumor (600 different runs
based on the same tumor (12 pipelines × 50 samples)).
Therefore, increasing the recall score by combining
variants, which are found by different pipelines, would
not be affected by any misclassified false positives as
our method proposes. Furthermore, our analysis of the
simulated dataset suggests that recall scores are poor on
low heterogeneity samples similar to the real dataset.
This work presents a framework for extensive analysis
of cancer sequencing pipelines. We plan to use this
framework on different data sets in future studies to have a
better understanding of pipeline performance in different
practical scenarios. The framework software is available
on GitHub2. We invite all interested parties to extend our
work.
Supplementary Data
Supplementary data can be accessed at the following link:
https://dx.doi.org/biy-2008-8-sup
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